<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="218">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05310071</url>
  </required_header>
  <id_info>
    <org_study_id>221AD305</org_study_id>
    <nct_id>NCT05310071</nct_id>
  </id_info>
  <brief_title>A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease</brief_title>
  <acronym>ENVISION</acronym>
  <official_title>A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to verify the clinical benefit of monthly doses of&#xD;
      aducanumab in slowing cognitive and functional impairment as measured by changes in the&#xD;
      Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in&#xD;
      participants with early Alzheimer's disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2022</start_date>
  <completion_date type="Anticipated">October 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 27, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in CDR-SB Score at Week 78</measure>
    <time_frame>Baseline, Week 78</time_frame>
    <description>The CDR integrates assessments from 3 domains of cognition (memory, orientation, judgment/problem-solving) and 3 domains of function (community affairs, home/hobbies, personal care). Following caregiver interview and systematic participant examination, the rater assigns a score describing the participant's current performance level in each of these domains of life functioning. The &quot;Sum of boxes&quot; scoring methodology (CDR-SB) sums the score for each of the 6 domains and provides a value ranging from 0 to 18 with higher scores indicating greater impairment. Positive change from baseline indicates greater impairment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score at Weeks 78 and 106</measure>
    <time_frame>Baseline, Weeks 78 and 106</time_frame>
    <description>The iADRS composite captures decline in both cognition and daily function. The iADRS is a simple linear combination of Alzheimer's disease assessment scale, cognitive subscale (ADAS-Cog13) and the Alzheimer's disease cooperative study scale for activities of daily living in mild cognitive impairment (ADCS-ADL-MCI). The iADRS scale ranges from 0-138, higher scores indicating better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ADCS-ADL-MCI Score at Weeks 78 and 106</measure>
    <time_frame>Baseline, Weeks 78 and 106</time_frame>
    <description>The ADCS-ADL-MCI is a functional evaluation scale for MCI participants, based on information provided by an informant who rates 18 areas of daily living, with total score ranging from 0-53. Higher scores indicate greater independent, healthy functioning. Positive change from baseline indicates healthy functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ADAS-Cog13 Score at Weeks 78 and 106</measure>
    <time_frame>Baseline, Weeks 78 and 106</time_frame>
    <description>The ADCS-ADAS-Cog13 is a brief objective cognitive assessment of the severity of cognitive symptoms of Alzheimer's disease. The ADAS-Cog13 score ranges from 0 to 85, with higher scores indicating worse performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mini-Mental State Examination (MMSE) Score at Weeks 78 and 106</measure>
    <time_frame>Baseline, Weeks 78 and 106</time_frame>
    <description>The MMSE is a brief cognitive screening tool that provides clinicians the ability to rapidly assess cognitive ability in less than 10 minutes. The MMSE score ranges from 0-30, with higher scores indicating better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neuropsychiatric Inventory-10 (NPI-10) Score at Weeks 78 and 106</measure>
    <time_frame>Baseline, Weeks 78 and 106</time_frame>
    <description>The NPI-10 is a questionnaire administered to the informant, designed to obtain information on the presence of neuropsychiatric symptoms and behaviors in a participant with Alzheimer's disease. Ten areas are assessed: delusions, hallucinations, agitation/aggression, depression, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability and aberrant motor behavior. The NPI total score ranges from 0 to 120. Higher scores indicates greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Amyloid Positron Emission Tomography (PET) Signal at Weeks 78 and 104</measure>
    <time_frame>Baseline, Weeks 78 and 104</time_frame>
    <description>The cerebral amyloid plaque level was measured by amyloid PET imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tau PET Signal at Weeks 78 and 104</measure>
    <time_frame>Baseline, Weeks 78 and 104</time_frame>
    <description>The cerebral tau level was measured by tau PET imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDR-SB Score at Week 106</measure>
    <time_frame>Baseline, Week 106</time_frame>
    <description>The CDR integrates assessments from 3 domains of cognition (memory, orientation, judgment/problem-solving) and 3 domains of function (community affairs, home/hobbies, personal care). Following caregiver interview and systematic participant examination, the rater assigns a score describing the participant's current performance level in each of these domains of life functioning. The &quot;Sum of boxes&quot; scoring methodology (CDR-SB) sums the score for each of the 6 domains and provides a value ranging from 0 to 18 with higher scores indicating greater impairment. Positive change from baseline indicates greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Global Statistical Test (GST) Composite Z-Score</measure>
    <time_frame>Baseline, Weeks 78 and 106</time_frame>
    <description>The GST is a composite z-score defined as the average of standardized z-scores of the CDR-SB, ADASCog13, and ADCS-ADL-MCI. A positive change from baseline indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1512</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Aducanumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive aducanumab, up to 10 milligrams per kilograms (mg/kg), monthly (once every four weeks), administered as intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo, monthly (once every four weeks), administered as IV infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aducanumab</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Aducanumab</arm_group_label>
    <other_name>BIIB037</other_name>
    <other_name>Aducanumab-avwa</other_name>
    <other_name>Aduhelm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  The participant must have confirmed amyloid beta pathology by cerebrospinal fluid&#xD;
             (CSF) or amyloid PET&#xD;
&#xD;
          -  Must have a history of subjective memory decline with gradual onset and slow&#xD;
             progression over the 6 months before Screening, confirmed by study partner&#xD;
&#xD;
          -  The participant must have 1 informant/care partner who, in the Investigator's opinion,&#xD;
             has frequent and sufficient contact with the participant (at least 10 hours/week in&#xD;
             person or by phone) as to be able to provide accurate information about the&#xD;
             participant's cognitive and functional abilities over time&#xD;
&#xD;
          -  Must meet all of the following clinical criteria for MCI due to Alzheimer's disease or&#xD;
             mild Alzheimer's disease according to National Institute on Aging and Alzheimer's&#xD;
             Association (NIA-AA) criteria&#xD;
&#xD;
               1. Have an MMSE score between 22 and 30 inclusive&#xD;
&#xD;
               2. Have a CDR memory score &gt;0.5&#xD;
&#xD;
               3. Have a Clinical Dementia Rating Scale Global Score (CDR-GS) of 0.5 or 1.0&#xD;
&#xD;
               4. Have a Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)&#xD;
                  score of 85 or lower indicative of objective cognitive impairment&#xD;
&#xD;
          -  Apart from a clinical diagnosis of early Alzheimer's disease, the participant must be&#xD;
             in good health as determined by the Investigator based on medical history and&#xD;
             screening assessments&#xD;
&#xD;
          -  Must consent to apolipoprotein E (ApoE) genotyping. (Note: Participants are not&#xD;
             required to be ApoE Îµ4 carriers)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Any uncontrolled medical or neurological/neurodegenerative condition (other than&#xD;
             Alzheimer's disease) that, in the opinion of the Investigator, might be a contributing&#xD;
             cause of the participant's cognitive impairment&#xD;
&#xD;
          -  Clinically significant and/or unstable psychiatric illness within 6 months prior to&#xD;
             Screening&#xD;
&#xD;
          -  Transient ischemic attack or stroke or any unexplained loss of consciousness within 1&#xD;
             year prior to Screening&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions or of hypersensitivity to any of&#xD;
             the inactive ingredients in the drug product&#xD;
&#xD;
          -  Participation in any study with purported disease-modifying effect in Alzheimer's&#xD;
             disease within 12 months prior to Screening unless documentation of receipt of placebo&#xD;
             is available&#xD;
&#xD;
          -  Current use or previous use of medications with a purported disease-modifying effect&#xD;
             in Alzheimer's disease, outside of investigational studies&#xD;
&#xD;
          -  Use of any medications that, in the opinion of the Investigator, may contribute to&#xD;
             cognitive impairment, put the participant at higher risk for AEs, or impair the&#xD;
             participant's ability to perform cognitive testing or complete study procedures&#xD;
&#xD;
          -  Use of any investigational drug&#xD;
&#xD;
          -  Prior exposure to aducanumab either commercially or by participation in a previous&#xD;
             study with aducanumab. (Participants are eligible if they did not receive active&#xD;
             aducanumab.)&#xD;
&#xD;
          -  A negative PET scan result with any amyloid-targeting ligand within 12 months prior to&#xD;
             Screening&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Clinical Trial Center</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Biogen Clinical Trial Center</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>954-659-5670</phone>
    </contact>
    <investigator>
      <last_name>David Weidman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>623-832-6500</phone>
    </contact>
    <investigator>
      <last_name>Danielle Goldfarb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuropain Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>559-437-9700</phone>
    </contact>
    <investigator>
      <last_name>Perminder Bhatia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anderson Clinical Research</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>909-792-9007</phone>
    </contact>
    <investigator>
      <last_name>Donald Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Syrentis Clinical Research</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-542-3008</phone>
    </contact>
    <investigator>
      <last_name>John Duffy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Neuroscience Research Medical Group Inc.</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>818-990-2671</phone>
    </contact>
    <investigator>
      <last_name>Thomas Shiovitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>203-401-4300</phone>
    </contact>
    <investigator>
      <last_name>David Russell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Center for Clinical Studies, Inc.</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06851</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>203-838-0070</phone>
    </contact>
    <investigator>
      <last_name>Bart Sloan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JEM Research Institute</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-968-2933</phone>
    </contact>
    <investigator>
      <last_name>Mark Goldstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-374-8464</phone>
    </contact>
    <investigator>
      <last_name>Paayal Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research, LLC</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>954-366-0277</phone>
    </contact>
    <investigator>
      <last_name>Harvey Schwartz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>352-629-5800</phone>
    </contact>
    <investigator>
      <last_name>Anette Nieves</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>K2 Medical Research, LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-729-3677</phone>
    </contact>
    <investigator>
      <last_name>Nicholas Weber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>K2 Medical Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-670-5833</phone>
    </contact>
    <investigator>
      <last_name>Sheila Baez-Torres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Headlands Research LLC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-705-3471</phone>
    </contact>
    <investigator>
      <last_name>Christopher Galloway</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research (Kane Center)</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34997</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>561-374-8464</phone>
    </contact>
    <investigator>
      <last_name>Paayal Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USF Health Byrd Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>813-974-4355</phone>
    </contact>
    <investigator>
      <last_name>Amanda Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hawaii Pacific Neuroscience</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>808-263-4476</phone>
    </contact>
    <investigator>
      <last_name>Kore Liow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute, Inc.</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>913-588-0555</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Burns</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension Via Christi Research, a division of Ascension Via Christi Hospitals Wichita, Inc.</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>316-291-4774</phone>
    </contact>
    <investigator>
      <last_name>Paul Murphy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Center for Memory</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-699-6927</phone>
    </contact>
    <investigator>
      <last_name>Paul Solomon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic, PA</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>601-579-5016</phone>
    </contact>
    <investigator>
      <last_name>Ronald Schwartz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Las Vegas Medical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>702-750-0222</phone>
    </contact>
    <investigator>
      <last_name>Bharat Mocherla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices and Research</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>978-655-7155</phone>
    </contact>
    <investigator>
      <last_name>Marc Shay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Memory Research Institute of NJ, PC</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>732-341-9500</phone>
    </contact>
    <investigator>
      <last_name>Sanjiv Sharma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological Associates of Albany, PC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>518-449-2662</phone>
    </contact>
    <investigator>
      <last_name>Richard Holub</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC Research, LLC</name>
      <address>
        <city>Matthews</city>
        <state>North Carolina</state>
        <zip>28105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>704-364-4000</phone>
      <phone_ext>225</phone_ext>
    </contact>
    <investigator>
      <last_name>Mohammad Reza Bolouri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>405-602-3939</phone>
    </contact>
    <investigator>
      <last_name>Carl Griffin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central States Research, LLC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>918-645-5400</phone>
    </contact>
    <investigator>
      <last_name>Sarah Land</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates, LTD</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-957-9250</phone>
    </contact>
    <investigator>
      <last_name>David Weisman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Mood &amp; Memory Research Institute</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02915</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>401-435-8950</phone>
    </contact>
    <investigator>
      <last_name>John Stoukides</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>401-455-6403</phone>
    </contact>
    <investigator>
      <last_name>Meghan Riddle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Clinic, PC</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>901-866-9252</phone>
    </contact>
    <investigator>
      <last_name>Lee Stein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Senior Adult Specialty Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>512-476-3556</phone>
    </contact>
    <investigator>
      <last_name>Jaron Winston</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kerwin Research Center and Memory Care</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972-433-9154</phone>
    </contact>
    <investigator>
      <last_name>Diana Kerwin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Memory Clinic</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>413-281-0576</phone>
    </contact>
    <investigator>
      <last_name>Cynthia Murphy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Clinical Research Inc. - Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>804-672-2995</phone>
    </contact>
    <investigator>
      <last_name>John Scott</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingfisher Cooperative, LLC</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>509-747-5615</phone>
    </contact>
    <investigator>
      <last_name>David Greeley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>March 25, 2022</study_first_submitted>
  <study_first_submitted_qc>March 25, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2022</study_first_posted>
  <last_update_submitted>October 13, 2022</last_update_submitted>
  <last_update_submitted_qc>October 13, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/</ipd_description>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

